Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes

Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as Siglec-15. Presently, small molecule inhibitors targeting Siglec-15 are not explored alongside characterised regulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Mohammed Saqif, Braoudaki, Maria, Patel, Hershna, Ahmad, Irshad, Shagufta, Siddiqui, Shoib Sarwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587484/
https://www.ncbi.nlm.nih.gov/pubmed/37869015
http://dx.doi.org/10.3389/fimmu.2023.1254911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587484/
https://www.ncbi.nlm.nih.gov/pubmed/37869015
http://dx.doi.org/10.3389/fimmu.2023.1254911

Ejemplares similares